Opportunity to schedule a free 30 minute session to discuss any aspect of your business or business idea with a group of seasoned entrepreneurs.
Become a successful business person. We help you (women and men) increase your professional success, personal growth, and financial independence.
The ECenter understands the importance of funding. Some ventures need an angel investor for a first round of outside capital or, depending upon the idea stage, you might be looking to a venture capital firm to raise a Series A …
YourEncore was founded in 2003 to act as a retiree return program for Lilly, P&G and Boeing. Over the past 14 years, we’ve grown and evolved into a flexible resourcing and consulting community, supporting hundreds of clients ranging from global …
Validated assays, specimen handling procedures, and reagent sources for clinical pharmacodynamic studies and Training Certification
Patient-derived models including patient-derived xenografts and in vivo patient-derived cell cultures annotated with clinical observations and molecular characterizations
Provides a focused consultation with NCI staff regarding the critical path considerations for developing novel investigational drugs intended for human use (i.e. small molecule or biologic, therapeutic or imaging drugs) and how to effectively communicate with the FDA.
Helps researchers identify potentially promising combinations of cancer drugs by providing data and analysis tools showing how well pairs of FDA-approved cancer drugs performed in killing tumor cells from the NCI-60 Human Tumor Cell Lines.
Navigator is a resource for investigators who have typically conducted exploratory correlative analysis and are now seeking specimens to validate their hypotheses.
This software provides an easy to use, fast compiled C program that runs in a DOS window for computing optimal and minimax two-stage designs for phase II clinical trials.
Through its Clinical and Translational Science Awards (CTSA) Program, NCATS is developing a single institutional review board (IRB) platform for multisite clinical studies: the NCATS Streamlined, Multisite, Accelerated Resources for Trials (SMART) IRB Platform. The goal is to provide flexible …
Knowing therapy development is a challenging process, NINDS asked its biologic consultant contractors to generate guidance documents to better prepare investigators.
Screening services, molecular targeting, drug development services
ResearchMatch is a free, secure registry, making it easier for the public to volunteer and to become involved in clinical research studies that contribute to improved human health. The tool is expected to reduce recruitment costs, increase enrollment and speed …
REDCap is an easy-to-use, freely available tool for clinical study management and data capture, providing investigators with the ability to build and manage online surveys and databases.
Offers well-established, broadly validated measures of phenotypic traits and environmental exposures of interest to investigators in human genomics, epidemiology and biomedical research.
Public website developed by NIH’s National Institute of Allergy and Infectious Diseases to help researchers navigate country-specific regulatory information as they plan and implement clinical trials.
Online glossary developed by a Food and Drug Administration and NIH joint committee to clarify terms used in translational science and medical product development, with a focus on study endpoints and biomarkers.
A standardized contract model designed to reduce negotiation time and contracting delays for industry-sponsored multi-site clinical studies, including Phase IIb and Phase III trials.
Training workshops designed to share best practices and advice on robust assay design, development and implementation for researchers involved in the drug discovery process.
The Assay Guidance Manual initiative delivers resources on best practices within the early stages of development as well as training focusing on robust, early-stage drug discovery assays.
The BrIDGs program assists researchers in advancing promising therapeutic agents through late-stage pre-clinical development toward an Investigational New Drug (IND) application and clinical testing.
TRND program supports pre-clinical development of therapeutic candidates intended to treat rare or neglected disorders, with the goal of enabling an Investigational New Drug (IND) application.